Effects of exercise on reducing treatment-side effects in prostate cancer patients undergoing hormone therapy
Completed
- Conditions
- Prostate cancer, androgen deprivation therapy (ADT)Cancer - Prostate
- Registration Number
- ACTRN12607000263493
- Lead Sponsor
- Edith Cowan University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 60
Inclusion Criteria
Prostate cancer patients undergoing androgen deprivation therapy for at least 2 months and who are anticipated to remain hypogonadal for the duration of the study (12 weeks), consent from physician, and able to walk 400m and undertake upper and lower body exercises.
Exclusion Criteria
Bone metastases, musculoskeletal, neurological or cardiovascular disorder that could inhibit the participant from exercising, participated in regular (e.g. 2 to 3 times per week) resistance training in the previous 12 months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Muscle function: muscle strength and muscle endurance.[Baseline and post-test (12 weeks).];Cardiorespiratory capacity: maximum oxygen uptake measured during a staged walking test on a motorized treadmill.[Baseline and post-test (12 weeks).];Physical performance: repeated chair rise, usual and fast 6-m walk, 6-m backwards walk, stair climb, and 400-m walk.[Baseline and post-test (12 weeks).];Body composition: whole body and regional muscle and fat tissue mass.[Baseline and post-test (12 weeks).];Balance and risk of falling: Neurocom Smart Balancemaster will be used to assess static and dynamic balance.[Baseline and post-test (12 weeks).]
- Secondary Outcome Measures
Name Time Method Health-related quality of life: EORTC QLQ-C30 and EORTC QLQ-PR25. <br>[Baseline and post-test (12 weeks).];Blood markers: prostate specific antigen (PSA), testosterone, insulin, growth hormone, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and plasma glucose. [Baseline and post-test (12 weeks).]